Signal transducer and activator of transcription 3 (STAT3) is an important transcription factor involved in a wide variety of cellular functions. Germline loss-of-function mutations are known to cause hyper-IgE immunodeficiency (autosomal dominant hyper IgE syndrome), whereas somatic gain-of-function mutations have been described in large granular cell leukemia, and polymorphisms in STAT3 have been associated with inflammatory bowel disease and other solid organ tumors. The review examines recent discoveries in our understanding of the nonmalignant disease processes affected by STAT3 mutations in human disease.
INTRODUCTION
Signal transducer and activator of transcription 3 (STAT3) is an important transcription factor that transmits signals to the nucleus after cytokine stimulation. After cytokine stimulation, the Janus kinase (JAK) phosphorylates the cytokine receptor, which activates cytokine receptor-associated kinases which tyrosine phosphorylate STATs. Then, two STAT molecules homo or heterodimerize via their Src homology 2 domain and translocate to the nucleus to bind to specific DNA elements to regulate gene expression [1] . STAT3 promotes and regulates the transcription of target genes involved in proliferation, apoptosis, and differentiation [2] . STAT3 is important in modulating both innate and adaptive responses through several cytokines including interferons, interleukin (IL)-2, IL-6, IL-7, IL-10, IL-12, IL-15, IL-21, IL-23, and IL-27 [3] . Dominant negative loss-of-function mutations in STAT3 cause the autosomal dominant hyper-IgE syndrome [autosomal dominant hyper IgE syndrome (AD-HIES) or Job's syndrome] characterized by recurrent bacterial lung and skin infections associated with cold abscess formation, severe eczematoid rash, chronic mucocutaneous candidiasis, primary structural connective tissue abnormalities and arterial tortuosity/ aneurysm formation. This loss-of-function does not correspond to a complete absence of the protein or of its function as the complete absence of STAT3 has not been seen in humans, and is lethal in mice [4] . Homodimerization of the wild-type protein allows for a residual function of about 20-30%. Gain of STAT3 function has classically been associated with neoplasms [5] and specific somatic mutations in STAT3 have been reported in a large subset of large granular lymphocyte leukemia patients [6] . Studying patients with STAT3 mutations continues to reveal critical biological pathways in which STAT3 participates, and how they affect normal human function as well as disease. The purpose of this review is to report the recent literature on STAT3 germline diseases and the effects on the immune system. Candidiasis, bacterial infection and abnormal IL-17-producing cells in patients with signal transducer and activator of transcription 3 loss-of-function STAT3 mutations in AD-HIES were first reported in 2007. Since then, a number of fundamental findings regarding STAT3 function in a variety of immunologic and nonimmunologic pathways have been revealed as a direct result of the study of these patients [7, 8] . One of the first such observations was that the patients, whose only common fungal disease was mucocutaneous candidiasis, lacked capacity to generate IL-17 producing T cells and normally upregulate retinoic acid-related orphan receptor gamma t (RORgt), the master transcription factor for Th17 cells [9] [10] [11] [12] . Subsequent work studying genes directly in the IL-17 pathway has borne out that IL-17, a fundamental cytokine in T-helper biology, appears to be responsible largely just for host defense against candidiasis and perhaps some staph infection, which is also seen in AD-HIES. More recently, patients with loss-of-function mutations in RORC, the gene which encodes RORgt in humans, were described [13 & ]. Interestingly, in addition to the expected inability to generate Th17 cells and resultant candidiasis, the patients also failed to mount a normal IFNg response to mycobacteria, leading to opportunistic mycobacterial infection [13 & ]. This was a surprising finding given that no such defect or infectious predilection is seen in AD-HIES despite the impaired capacity for RORgt upregulation [14 & ]. This observation might be partially explained by the recent finding that while unconventional T cells (which could have roles in antimycobacterial immunity) such as natural killer T cells and mucosal-associated invariant T cells (MAIT cells) are reduced in AD-HIES, the MAIT at least express normal levels of RORgt [15 && ].
Viral reactivation and antibody defects: impact of signal transducer and activator of transcription 3 on T-cell memory, T cell, and natural killer cell cytotoxicity and B-cell help
Patients with HIES have an increased rate of reactivation of chronic herpes virus infections, EpsteinBarr virus and varicella-zoster virus in particular [16, 17] . This susceptibility was thought to be at least in part because of a reduction in central memory CD4
þ T cells in AD-HIES [16, 17] . In addition, the cytokine IL-21, which can activate STAT3, was shown to be critical for CD8
þ T-cell function in vitro and increase survival and proliferation of mouse central memory CD8 þ T cells [18] . It induces important effector molecules in CD8 þ T cells, such as IFN-g, granzyme B, and perforin [19] [20] [21] [22] . Ives et al. [23] used the AD-HIES model to study the effects of IL-21 on STAT3 signaling on the homeostasis and function of human CD8 þ effector T cells, finding a decrease in central and effector memory T-cell numbers in the STAT3 deficient patients. More intriguingly, STAT3 signaling appeared to be critical for certain forms of CD8 þ and natural killer mediated cytotoxicity. Natural killer group 2D (NKG2D) is an activating receptor that plays a critical role in the immune response mediated by natural killer cells to viral infections [24] . STAT3 activation through IL-21 stimulation increases the expression of NKG2D in natural killer cells, which is lower in conditional STAT3 deletion and natural killer cells of AD-HIES patients [25 && ]. Therefore, it is possible that the viral reactivation defect in STAT3 deficient patients may be affected by abnormalities in CD8 þ T-cell and natural killer cell viral defense; although of interest, primary viral infections are not particularly pathogenic in AD-HIES [23] .
The abnormal B-cell function and antibody responses in AD-HIES are likely because of the role for STAT3 in follicular helper T-cell differentiation and IL-21 signaling in naïve B-cell differentiation [11, 26] . Although memory B-cell levels are
KEY POINTS
The study of AD-HIES has significantly increased our knowledge of the diverse functions of STAT3 in the immune system. STAT3 plays a role in regulation of T-cell subsets as well as mast cells and natural killer cells.
Gain of function of STAT3 leads to an early onset autoimmune disease characterized by immunodeficiency and lymphoproliferation.
The study of new disease phenotypes in known genes leads to discovery of novel disease pathways.
decreased, antibody levels are largely normal in AD-HIES, likely attributable to the observation that the few circulating B cells found in these patients are capable of differentiating into antibody-secreting plasma cells suggesting a STAT3 independent plasma cell differentiation pathway [27] .
Signal transducer and activator of transcription 3 and allergy STAT3 deficient patients have an increased level of IgE but paradoxically appear to be relatively protected from atopic disease [28,29 && ] . In that regard, AD-HIES patients stand in stark contrast to other genetic diseases associated with infection and marked IgE elevation, such as dedicator of cytokinesis 8 (DOCK8) and phosphoglucomutase 3 (PGM3) deficiencies. One observed mechanism appears to be a relative impairment of mast cell and basophil degranulation in the context of STAT3 mutations [28] . There may also be a role for STAT3 in generating allergen-specific IgE. While Siegel et al. [28] saw elevated levels of food allergen-specific IgE, Boos et al. [29 && ] saw no increase in allergen-specific IgE to a large variety of allergens or any increased skin prick test positivity compared to nonatopic controls.
Increased signal transducer and activator of transcription 3 function in autoimmunity and lymphoproliferation
STAT3 function has been linked to increased cell survival and autoimmunity in a variety of experimental models [3, [30] [31] [32] . Somatic activating gain-of-function (GOF) STAT3 mutations in the Src homology 2 domain have been described in patients with T-cell and natural killer cell large granular cell leukemia characterized by adult-onset lymphoproliferation, as well as autoimmunity with immune-mediated cytopenias [6, 33] . Genome wide association studies have also linked a STAT3 polymorphism to inflammatory bowel disease [34, 35] . Additionally, in a meta-analysis of ulcerative colitis and crohn's disease genome wide association studies with 75 000 cases and controls, there was overlap with inflammatory bowel disease loci, including STAT3 and mycobacterial disease [36] .
It is in that context that several groups recently identified a syndrome of early onset autoimmunity and lymphoproliferation with highly variable penetrance and presentation in 19 individuals with germline heterozygous STAT3 mutations ( ]. Patients presented with a wide spectrum of lymphoproliferative and autoimmune disease, including enteropathy, lymphocytic interstitial lung disease, and autoimmune cytopenias, associated with growth delay, endocrinopathies (diabetes), hepatic dysfunction, and susceptibility to opportunisitic infections including mycobacterial disease. Among these 19 patients, the clinical manifestations are very diverse: early-onset type 1 diabetes (n ¼ 6); short stature (n ¼ 12); autoimmune cytopenias (n ¼ 14); lymphadenopathy (n ¼ 11); lymphoproliferation (n ¼ 10); intestinal manifestations (n ¼ 9), including enteropathy (n ¼ 6), celiac disease (n ¼ 2) and nonspecific colitis (n ¼ 1); cutaneous manifestations (n ¼ 9), including eczema (n ¼ 6), alopecia (n ¼ 2), and non-specific dermatitis (n ¼ 1); autoimmune lung disease (n ¼ 6); arthritis (n ¼ 3); and uveitis (n ¼ 1). All patients in Haapaniemi's cohort presented with hypogammaglobulinemia, associated with decreased switched memory B cells, natural killer cells and plasmacytoid dendritic cells. In Milner's cohort, five patients had hypogammaglobulinemia, three had a T-cell lymphopenia, and one had B-cell lymphopenia. A majority of patients presented with recurrent infections (n ¼ 11), including fungal infections Many of the observed immune abnormalities were consistent with increased STAT3 activity leading to suppression of other STAT pathways. Milner et al. reported decreased T regulatory cells and impaired STAT5 activation reminiscent of patients with loss-of-function STAT5b who have numerous overlapping symptoms with GOF STAT3 patients, including short stature, enteropathy, cytopenias, lymphocytic interstitial lung disease, and endocrinopathies [41] . They also found diminished STAT1 phosphorylation, which could potentially account for other immune regulatory defects, as well as the mycobacterial disease observed in a subset of the patients [39 && ]. The STAT1/STAT5 defects may be explained by increased expression of suppressor of cytokine signaling 3 (SOCS3), a STAT3 target which also serves as a negative regulator of STAT3 [42] , STAT1, and STAT5 [42] . The precise cause of the observed infections is difficult to ascertain since most of the patients have been on chronic immune suppression; however, the antibody defects as well as some of the cellular defects were observed in a handful of patients off immune suppression as well. Immunosuppression was the key to therapeutic intervention in these patients. Blocking IL-6 activation with Tocilizumab in one patient resulted in a dramatic improvement in arthritis and a reduction of TH-17 numbers to normal levels. Hematopoietic stem cell transplantation was performed in two patients; one was curative in one patient with complete resolution of autoimmune symptoms and the other patient died of adenovirus infection and refractory graft vs. host disease [39 && ,40] . Surprisingly, despite the connection between increased STAT3 activity and neoplastic disease, as well as the observation that somatic GOF mutations in STAT3 lead to large granular lymphocyte, neoplastic disease was quite rare in the cohorts reported. One patient developed T-cell large granular lymphocytic leukemia at age 14 [38 & ].
CONCLUSION
Studying patients with STAT3 loss-of-function in AD-HIES and GOF in the lymphoproliferative STAT3 disease, we gain key insights into the role STAT3 plays in regulation of the immune system. The wide range of phenotypes demonstrates the diversity of function of STAT3 in the immune system and its tight regulation. Further examination of these disorders will continue to reveal both the cellular consequences of disturbing such regulation, as well as the clinical manifestations. 
